Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients

BACKGROUND: This meta-analysis aimed to test the hypothesis that the HER2-positive metastatic breast cancer (mBC) patients treated with anti-HER2 antibodies in trial intervention arms have a greater prolongation of overall survival (OS) than of progression-free survival (PFS) and this extra-prolonga...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, I-Chun, Hu, Fu-Chang, Lin, Ching-Hung, Huang, Shu-Min, Chang, Dwan-Ying, Cheng, Ann-Lii, Lu, Yen-Shen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321956/
https://www.ncbi.nlm.nih.gov/pubmed/34298300
http://dx.doi.org/10.1016/j.breast.2021.07.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321956/
https://www.ncbi.nlm.nih.gov/pubmed/34298300
http://dx.doi.org/10.1016/j.breast.2021.07.006

Ejemplares similares